Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|June 29, 2011
Almac Expands Global Coverage by Adding Depots for Clinical Trial Supply Distribution to the Asia Pacific Region
Advertisement
Almac’s Clinical Services
have increased its presence in the Asia Pacific region. It has extended its reach by adding five new depots located in—Japan, Thailand, Hong Kong, Taiwan to its extensive global depot network. These latest developments in the Asian market enable Almac to provide customers with even more flexibility in their supply chain solution for their specific country clinical trial requirements. The number of depots within the Network is now 36 with a further five planned for 2012.
As part of Almac’s continued expansion of services globally they have also sought to expand their controlled drug network in Europe to ensure they have a network capable of storing this class of drugs within each EU country.
Almac’s Global Depot Network
is managed by dedicated depot management teams who serve as the central contact point for the network and also perform regular visits to the depots which are fully audited and GMP compliant. In line with continuous depot expansion the resources within the Depot Management Team have also increased over the past six months. There are now 15 members of staff who are located in the UK, USA, and Brazil that are dedicated to managing protocols across the depot network.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5